Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting. The AACR Annual Meeting, held from April 8th to 13th in New Orleans, is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
Recent Posts
See AllRakovina Therapeutics’ management will deliver a brief corporate overview and then be available for questions and discussions...
Pre-clinical studies show potential synergy in treatment of solid tumors by combining a PARP inhibitor with inhibition of HDAC enzymes.